Gilead Sciences (GILD) closed the most recent trading day at $83.62, moving -0.54% from the previous trading session.
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Consider investing in stocks that have both attractive growth opportunities and that pay an above-average dividend. Before the end of last year, Gilead Sciences investors received some great news: The company's twice-yearly injectable treatment for HIV obtained approval from the Food and Drug Administration. With the approval, Gilead has added a potential blockbuster to its portfolio as analysts project Sunlenca could hit a peak of $1.5 billion in annual revenue.